Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Carbamide + hydrocortisone is a topical combination drug used primarily for the treatment of inflammatory skin conditions such as eczema, atopic dermatitis, psoriasis, and other dermatoses characterized by inflammation and hyperkeratosis. Hydrocortisone is a corticosteroid that reduces inflammation by suppressing the immune response and decreasing the release of inflammatory mediators. Carbamide (urea) acts as a keratolytic agent that softens and moisturizes the skin by increasing water uptake in the stratum corneum. The combination leverages both anti-inflammatory effects (from hydrocortisone) and hydration/keratolytic effects (from carbamide), making it suitable for chronic or hyperkeratotic skin disorders where both inflammation control and barrier repair are needed[9][10][7]. Clinical studies suggest this combination can be effective with fewer side effects compared to more potent corticosteroids[7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on carbamide + hydrocortisone.